Clinical patterns of vitiligo in Japan: A descriptive study using the JMDC claims database

Area of Science:

• Dermatology
• Autoimmune Disorders
• Epidemiology

Background:

• Vitiligo is a chronic autoimmune condition significantly affecting patient quality of life.
• Real-world data on vitiligo epidemiology in Japan is limited.
• Understanding prevalence, comorbidities, and treatment patterns is crucial for effective patient management.

Purpose of the Study:

• To evaluate the prevalence, patient demographics, comorbidities, and treatment patterns of vitiligo in Japan using real-world data.
• To analyze trends in vitiligo prevalence and associated conditions over a 13-year period.
• To identify common comorbidities and treatment modalities utilized by Japanese vitiligo patients.

Main Methods:

• A descriptive, cross-sectional study utilizing a large Japanese claims database (JMDC) from 2010 to 2022.
• Inclusion criteria: patients with claims for a vitiligo diagnosis.
• Analysis included annual prevalence, comorbidity assessment, treatment utilization, and healthcare utilization metrics.

Main Results:

• Vitiligo prevalence in Japan was consistently around 0.16% (0.051% in 2010 to 0.056% in 2022).
• Atopic dermatitis was the most common comorbidity, increasing significantly over time, especially in children.
• Topical corticosteroids remained common but decreased in use, while narrowband ultraviolet B therapy use increased.

Conclusions:

• Vitiligo prevalence in Japan is stable, but the comorbidity burden, particularly atopic dermatitis, is substantial and increasing.
• Treatment patterns are evolving, with a shift towards phototherapy.
• These findings provide valuable insights for clinical practice and treatment guideline development for vitiligo patients in Japan.